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Abstract
Background: It is well documented that the mucosal linings of the female genital tract (FGT) usually provides a
robust barrier that protects against sexually acquired infections. However, to the best of our knowledge there are
limited South African studies that have investigated the association between damage to the mucosal linings and
the acquisition of HIV infections. We hypothesize that in this cohort of women, a higher rate of HIV seroconversions
will be observed for women who present with evidence of mucosal damage.
Methods: We undertook a secondary analysis of the Methods for Improving Reproductive Health in Africa (MIRA)
trial that assessed the effectiveness of the latex diaphragm and lubricant gel on HIV prevention among women.
Participants underwent a physical examination which included a pelvic examination to detect the presence of
mucosal abnormalities. During the physical examinations, the study clinicians examined the genitalia, cervix and
vagina for signs of epithelial disruptions and abnormal vaginal discharge. The association between the various
genital factors and HIV seroconversion was modeled using Cox proportional hazards regression analysis.
Results: In this cohort of 1485 women that had enrolled to participate in the study, women that had presented
with genital epithelial disruptions and abnormal vaginal discharge were shown to be at highest risk for HIV acquisition
(Hazard Ratio (HR): 4.30, 95 % CI: 2.25, 8.22, p <0001, HR: 2.37, 95 % CI: 1.69, 3.33, p <0.001) respectively. In addition, the
Kaplan Meier analysis showed that the highest number of seroconversions was observed in women that had disrupted
genital epithelia (27 per 100/py, 95 % CI: 15.0, 50.7) and abnormal vaginal discharge (12 per 100/py, 95 % CI: 9.70, 16.7).
Other significant factors included: genital signs and symptoms (HR: 1.67, 95 % CI: 1.07, 2.61, p = 0.02) and genital ulcers/
sores (HR: 1.79, 95 % CI: 1.05, 3.06, p = 0.03).
Conclusion: We have shown that damage to the mucosal epithelial lining increases a women’s risk of HIV
seroconversion. Future studies that provide an in depth understanding of the mechanisms associated with the FGT
and mucosal immunity will be most valuable. An understanding of all of these mechanisms will be key in directing the
advancement of products most suitable for combating HIV infection in women.
Trial registration: This study was registered with ClinicalTrials.gov,number NCT00121459 on the 28th February 2007.
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Background
In sub-Saharan Africa (SSA), 60 % of the adults living
with Human Immunodeficiency virus (HIV) infection
are women [1]. It is suggested that 30–40 % of these
infections occur through heterosexual transmission via
the female genital tract (FGT) [2]. The FGT is divided
into two main compartments; the lower reproductive
tract, consisting of the vagina and ectocervix, lined by
stratified squamous epithelium; and the upper repro-
ductive tract consisting of the endocervix, endomet-
rium and fallopian tubes, lined by a single layer of
columnar epithelium [2–4]. There are numerous char-
acteristics of FGT that have shown to increase suscep-
tibility to HIV infection [5]. One of the characteristics
included local changes in the FGT induced by infec-
tion by other microorganisms [5]. Evidence from la-
boratory, clinical as well as epidemiological studies
have supported the hypothesis that sexually transmit-
ted infections (STIs) facilitate the spread of HIV [6].
Sexually transmitted infections have been found to fa-
cilitate HIV transmission by rupturing protective mu-
cosal barriers and recruiting susceptible immune cells
(eg. CD4 T-helper cells, macrophages) to the site of
infection [7]. Sexually transmitted infections have also
been considered major causes of inflammatory cyto-
kine up-regulation and recruitment of immune cells to
the genital mucosa [8, 9]. South African studies have
showed that Chlamydia trachomatis, Neisseria gonor-
rhoeae, Mycoplasma genitalium infections and ele-
vated cervicovaginal lavage (CVL) concentrations of
interleukin (IL)-1β, IL-6, IL-8 and soluble CD40L
(sCD40L) are associated with increased risk of HIV ac-
quisition [10].
Many epidemiological studies have found a strong
association between HSV-2 infection and HIV infec-
tion [11]. Some studies have reported high prevalence
rates in the general population as well as high risk
populations. The prevalence of HSV-2 was shown to
be >50 % among women and >25 % among men in Sub
Saharan Africa [12]. In a more recent study by Abbai
et al. [13], the prevalence of HSV-2 and HIV-1 co-
infection was reported to be 41 % in women in South
Africa. The increased susceptibility to HIV is most
likely due to HSV-2-induced ulcerations, which rup-
tures the physical barrier of the genital epithelium [2].
Studies conducted using a Simian immunodeficiency
virus (SIV) model has shown that damage to the mu-
cosal barrier before SIV infection predicts disease pro-
gression to AIDS after infection, demonstrating the
importance of barrier health even before infection oc-
curs [14].
To the best of our knowledge there are limited
South African studies that have investigated the asso-
ciation between damage to the mucosal linings and
the risk for HIV acquisition. We hypothesize that in
this cohort of women, a higher rate of HIV serocon-
versions will be observed for women who present
with evidence of mucosal damage. Identifying women
who present with mucosal damage could facilitate ef-
forts that are directed towards developing products
that cover the cervix and has the potential to offer
safe and effective protection against HIV and other
STIs. However, efforts should not be solely focused
on diaphragms since diaphragms have provided no




The Methods for Improving Reproductive Health in
Africa (MIRA) study which assessed the effectiveness
of the latex diaphragm with a lubricant gel in prevent-
ing heterosexual acquisition of HIV among women in
southern Africa was conducted between 2003–2005 in
South Africa (Durban) and Zimbabwe [15]. However,
the provision of diaphragms and lubricant gels in
addition to male condoms provided no beneficial ef-
fect [15]. This analysis is based only on participants
recruited and enrolled at the Durban sites. In Durban,
the study was conducted in rural Umkomaas (a peri-
urban region located 60 km south of Durban) and
Bothas Hill (a rural area located 40 km west of
Durban).
Study participants
Of the 3472 women screened at the Durban research
sites, 1485 women were enrolled into the study. The
study population has been described in greater detail
elsewhere [15]. Women were recruited from family plan-
ning, well-baby and general health clinics for participa-
tion in this study. The main eligibility criteria for the
study included: women aged 18 to 49 years old, sexually
active (coital frequency at least four times per month on
average), HIV-negative based on testing within 14 days
prior to enrollment, Chlamydia trachomatis- and Neis-
seria gonorrhoeae-negative based on testing within
30 days prior to enrollment or, if positive, completes
treatment before enrollment, have a healthy cervix as
assessed by naked-eye speculum exam at enrollment,
planning to live in the study area for the duration of the
study, and willing and able to give informed consent.
Participants provided written informed consent prior to
study procedures being conducted. Participants were
followed quarterly with a mean follow-up of 18
woman-months per participant. Participants had com-
pleted physical examinations at all study visits to iden-
tify any abnormalities of the cervix and to detect any
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cervicovaginal infections. Testing for HIV and STIs
were also done at all study visits.
Ethics
The original trial study was reviewed and approved by
the University of California at San Francisco Institu-
tional Review Board Committee on Human Research,
and by the ethics review committees at all local insti-
tutions and collaborating organizations, including the
Medical Research Council of Zimbabwe, the Medi-
cines Control Authority of Zimbabwe, Biomedical
Research Ethics Committee of the University of
KwaZulu-Natal, Human Research Ethics Committee of
the University of the Witwatersrand, and Western In-
stitutional Review Board. This study was registered
with ClinicalTrials.gov,number NCT00121459 on the
28th February 2007. Approval to use any data for sec-
ondary analysis has been previously granted by the
MIRA protocol team.
Clinical data collection
At screening (baseline visit), women were interviewed
by the study staff to collect information on demograph-
ics (age, marital status, religion, language spoken) and
sexual behavior (number of lifetime sexual partners,
age of sexual debut, sex in exchange for goods, condom
use and coital frequency). Data collected on clinical
history included data on treatment of STIs or repro-
ductive tract infections, symptoms of genital ulcers,
genital warts and abnormal vaginal discharge, pain in
urinating, genital signs, genital irritation, painful urin-
ation and pain during intercourse. All of the above
mentioned data was collected by interviewer adminis-
tered questionnaires and the data recorded was based
on self-report. Participants underwent a physical exam-
ination which included a pelvic examination to detect
the presence of mucosal abnormalities. The external
genitalia, cervix and vagina were inspected with the
naked eye. During the physical examinations, the study
clinicians examined the perineum/perianal, vulva and
vaginal epithelium of the women for signs of epithelial
disruptions. Epithelial disruption was defined as a break
in the lining of the epithelium thereby exposing the
subcutaneous tissue. All women that had participated
in the study were compensated (monetary compensa-
tion) for their time spent at the research clinic.
Laboratory procedures
Two HIV rapid tests were done on whole blood sam-
ples collected by venipuncture. The rapid tests used
were the Determine HIV-1/2 (Abbott Laboratories,
Japan) and Oraquick (OraSure Technologies, USA).
Urine specimens were collected for polymerase chain
reaction (PCR) testing for Neisseria gonorrhea (NG),
Chlamydia trachomatis (CT) and Trichomonas vagina-
lis (TV) (Roche Pharmaceuticals, USA). Whole blood
samples were also collected for the testing of syphilis
and HSV-2. Testing for syphilis was conducted using
the Rapid plasma regain (RPR) and Treponema palli-
dum haemagglutinin [TPHA], Randox Laboratories,
Crumlin, UK). Testing for HSV-2 was conducted using
a HSV2 ELISA assay (FOCUS Diagnostics, Cypress,
CA, USA). The presence of bacterial vaginosis (BV)
and candidiasis were based on vaginal pH and wet
mount tests.
Data analysis
The biological factors that formed part of the analysis
plan included: pre-existing STIs, genital ulcer/sores,
reproductive tract infections, abnormal vaginal dis-
charge, genital signs and symptoms, genital discharge,
genital irritation, genital disruption and the presence
of genital warts. The date of seroconversion was esti-
mated using the midpoint between the last negative
and the first positive antibody test results within the
follow-up period. Cox regression models were used to
assess the associations between the risk factors and
HIV seroconversion. The analysis was conducted after
adjusting for age, number of lifetime sexual partners,
marital and cohabitation status, age of sexual debut
and education level. Kaplan-Meier survival analyses
was carried out to estimate the crude HIV serocon-
version rates taking into consideration the variables
that were strongly associated with HIV risk such as epi-
thelial disruptions and vaginal discharge. Statistical ana-
lysis was performed using STATA release 12.0 (College
Station, Texas, TX, USA).
Results
The baseline characteristics of the study population is
described in Table 1. In our cohort of 1485 women that
had enrolled to participate in the study, most of the
women were younger than 25 years of age (42 %) and
had experienced first sex after the age of 16 years (62 %).
More than half of the women had not attained a high
school qualification (72 %). Most women were unmar-
ried (77 %), non-cohabiting (62 %) and unemployed
(80 %). The coital frequency in these women was re-
ported to be low with most women having had sex <3
times in the past week (77 %). Approximately one-third
of the women reported having one lifetime sex partner
(33 %) and not having used condoms in the past
3 months prior to enrollment (35 %). In addition, most
women were diagnosed with HSV-2 infection (66 %)
whereas fewer women were diagnosed with non-
ulcerative STIs such as N. gonorrhoeae, C. trachomatis,
and T. vaginalis (17 %). Fewer women reported experi-
encing abnormal vaginal discharge (18 %).
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The predictors of future HIV infections is described
in Table 2. A history of pre-existing STIs such as N.
gonorrhoeae, C. trachomatis and T. vaginalis was not
significantly associated with the risk for future HIV
infections (Hazard ratio (HR) 1.05, 95 % Confidence
Interval (CI): 0.70, 1.57, p = 0.81). Similarly, being di-
agnosed with syphilis was not shown to be associated
with incident HIV infections (HR: 0.58, 95 % CI: 0.21,
1.58, p = 0.29). Similar observations were made with
the data obtained on reproductive tract infections
such as candidiasis (p = 0.30) and bacterial vaginosis
(p = 0.19). However, having a pre-existing HSV-2 in-
fection was shown to be strongly associated with inci-
dent HIV infections (HR: 1.72, 95 % CI: 1.01, 2.94, p
= 0.004).
According to the findings of the physical examina-
tions, disruption of the genital epithelium (HR: 4.30,
95 % CI: 2.20, 8.21, p <0001 and abnormal vaginal
discharge (HR: 2.22, 95 % CI: 1.57, 3.21, p = <0.001)
were the factors that were the strongest predictors for
HIV acquisition. Other significant factors included:
genital signs (HR: 1.62, 95 % CI: 1.04, 2.54, p = 0.03)
and the presence of genital ulcers/sores (HR: 1.72,
95 % CI: 1.01, 2.94, p = 0.04). However, factors such
as genital irritation, pain during sex, painful urination,
vaginal bleeding, and the presence of genital warts
were not significantly associated with the risk for fu-
ture HIV infections.
Survival analysis
According to the Kaplan Meier survival estimates (Fig. 1),
the largest number of HIV-1 seroconversions was
observed with women that had symptoms of genital epi-
thelial disruption and abnormal vaginal discharge. Ap-
proximately more than 10 % of the women that had
showed signs of epithelial disruption seroconverted after
being enrolled in the study for about 3 months (Fig. 1a).
The overall crude HIV incidence rate associated with
epithelial disruption was reported to be 27 per 100 per-
son years (PY), (95 % CI: 15.0, 50.7). The overall crude
HIV incidence rate associated with abnormal vaginal
discharge was reported to be 12.7 per 100/PY, (95 %
CI: 9.70, 16.7). Most women who had showed signs
of abnormal vaginal discharge seroconverted after be-
ing enrolled in the study for approximately 12 months
(Fig. 1b).
Discussion
In our study, the largest number of HIV infections
were reported for women who presented with signs
of disruption of their genital epithelium and abnor-
mal vaginal discharge. Our findings are in keeping
with previous findings [16]. Pre-clinical studies with
the SIV/macaque vaginal transmission model has
Table 1 Baseline characteristics of the women enrolled in the
MIRA study at the Durban research sites
Variable Total N (%)
1485 (100)
Age
<25 years old 622 (42)
25–34 years old 455 (31)
>35 years old 407 (27)
Level of education
Less than high school 1074 (72)
At least high school 411 (28)
Employment status
Not employed 1194 (80)
Employed 291 (20)
Marital status









4 + 267 (18)
Coital frequency per week
<3 1145 (77)
>3 340 (23)




Age of sexual debut
<16 years of age 927 (62)
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shown that the normal genital tract is a substantial
barrier to viral transmission and that the disruption
of the epithelium is associated with enhanced HIV
acquisition [16]. A reason for the enhanced suscepti-
bility to HIV in women with epithelial disruptions
has been described by Mesquita et al. [17]. According
to Mesquita et al. [17], disruption of the vaginal epi-
thelial barrier has been shown to facilitate the move-
ment of HIV into the laminae propriae, where HIV
target cells are shown to be more abundant [17]. In
addition, clinical and epidemiological observation
studies have also reported that the disruption of the
vaginal epithelium is associated with enhanced HIV
acquisition [16].
Sexually transmitted infections are known to facilitate
HIV transmission by rupturing protective mucosal bar-
riers [7]. However, in our study, we found that women
who were diagnosed with STIs (N. gonorrhoea, C. tra-
chomatis and T. vaginalis) were not at increased risk of
HIV seroconversion. Our findings therefore differs from
numerous other published studies on the association
between HIV and STIs [18]. We assume that the STI
treatment that was provided to our study women
played an important role in protecting them from ac-
quiring HIV. Our assumption has been confirmed by
Morse et al. [19] who reported that effective treatment
of curable STIs as well as HSV-2 infections have been
shown to reduce the incidence of HIV infections in
African populations. Additionally, observational studies
also support the hypothesis that STI treatment can re-
duce HIV infectiousness [20].
The association between BV and HIV acquisition
has been well described in a systematic review by
Atashili et al. [21]. The review found that BV was
consistently associated with an increased risk of HIV
infection [21]. In our study, we found that women
who were symptomatic for BV were at increased risk
of HIV acquisition (HR 1.36), however, this result was
not statistically significant. The inability to detect sta-
tistically significant effects could be attributed to the
relatively small sample size of the women who had la-
boratory diagnoses completed for BV, resulting in re-
duced power.
In our study we found a large number of HIV serocon-
versions in women who reported abnormal vaginal dis-
charge when compared to women who did not report
any discharge. Our findings are consistent with a previ-
ous study that reported that vaginal discharge is com-
monly associated with women infected with HIV when
compared to uninfected women [22].
In addition, in our study, women who presented
with genital ulcers/sores were shown to be at risk for
HIV seroconversion. Our findings are in keeping with
previous reports that have shown genital ulcer dis-
eases (GUD) to be associated with HIV infection [23].
According to Røttingen et al. [24], the effects of
GUD, caused by HSV-2 on susceptibility to HIV ac-
quisition may be greater than the effects of non-
ulcerative STI symptoms (discharge, inflammation and
pelvic inflammatory disease). This is consistent with
our findings since women who were diagnosed with
HSV-2 infections were shown to be at increased risk
for HIV seroconversion. Herpes Simplex Virus type-2
has been shown to weaken the physical barrier to in-
fection among HIV uninfected individuals as well as
enhance the shedding of HIV among HIV infected in-
dividuals [6].
We acknowledge the following limitation of our study;
the data presented in this study is limited to the popula-
tion of women in which the research was conducted and
may not be representative of women in the general
population. However, the strength of the current study is
that the data used for the analysis was collected from
women who reside in the epicenter of the HIV epidemic
in Sub-Saharan Africa and the data generated will be
beneficial for developing and implementing prevention
strategies that protect women from these settings from
future infections.
In addition, to the best of our knowledge there
have been no published reports from South African
populations that have looked at the association of
genital factors such as epithelial disruption and HIV
Table 2 Predictors for future HIV-1 infections using Cox
proportional hazard models for women that had participated in
the MIRA study
Risk factors Hazard ratio (95 %
confidence interval)
p-value
Pre-existing STIsa 1.05 (0.70, 1.57) 0.81
Genital ulcer/sores 1.72 (1.01, 2.94) 0.04
Pain in urinating 1.01 (0.64, 1.57) 0.96
Pre-existing HSV-2 infection 1.72 (1.18, 2.51) 0.004
Pain during sex 1.22 (0.80, 1.86) 0.34
Genital irritation 1.26 (0.73, 2.20) 0.39
Genital epithelial disruptionb 4.3 (2.20,8.21) <0.001
Genital signs 1.62 (1.04, 2.54) 0.03
Candidiasis 1.45 (0.70, 2.96) 0.30
Abnormal vaginal discharge 2.22 (1.57, 3.12) <0.001
Bacterial vaginosis (symptomatic) 1.36 (0.85, 2.19) 0.19
Diagnosed with Treponema pallidum
(syphilis)
0.58 (0.21, 1.58) 0.29
Vaginal bleeding 1.39 (0.86, 2.26) 0.17
Warts 0.75 (0.10, 5.40) 0.78
aNeisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis
bVaginal, vulva, perineum
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seroconversion. Therefore, the findings from this
study add to the growing body of knowledge regard-
ing the biological factors that place women at risk
for incident HIV infections in our current setting.
Conclusions
In our study we have shown that damage to the mucosal
epithelial lining increases a woman’s risk of HIV sero-
conversion. Future studies that provide an in depth un-
derstanding of the FGT and mucosal immunity will be
most valuable since there are several mechanisms of
transmission that are present in the FGT [25, 26]. An
understanding of all of these mechanisms will be key in
directing the advancement of products most suitable for
combating HIV infection in women.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
NSA performed the data interpretations. GR was the clinical trials unit PI for
the study. HW completed the statistical analysis. NSA wrote the paper with
input from HW and GR. All authors read and approved the final manuscript.
Acknowledgements
We gratefully acknowledge the contribution of the women who participated
in this study. We thank the MIRA team at the University of California (San
Francisco), Ibis Reproductive Health and members of the HIV Prevention
Research Unit (MRC South Africa). We acknowledge the financial support of
the Bill and Melinda Gates Foundation (Grant number 21082).
Author details
1HIV Prevention Research Unit, Medical Research Council, 123 Jan Hofmeyr
Road, Westville, Durban 3630, South Africa. 2Department of Epidemiology
and Population Health, London School of Hygiene & Tropical Medicine,
Fig. 1 Kaplan Meier plots showing the survival rates for the individual genital factors with the crude HIV incidence rates calculated for each
variable with the respective p-values. a epithelial disruption and b abnormal vaginal discharge
Abbai et al. BMC Women's Health  (2016) 16:19 Page 6 of 7
London, UK. 3The Kirby Institute, University of New South Wales, Sydney,
NSW 2052, Australia.
Received: 16 August 2014 Accepted: 8 March 2016
References
1. Abaasa A, Crook A, Gafos M, Anywaine Z, Levin J, Wandiembe S, et al. Long-
term consistent use of a vaginal microbicide gel among HIV-1 sero-
discordant couples in a phase III clinical trial (MDP 301) in rural south-west
Uganda. Trials. 2013;14:33.
2. Kaushic C, Ferreira VH, Kafka JK, Nazli A. REVIEW ARTICLE: HIV infection in
the female genital tract: discrete influence of the local mucosal
microenvironment. Am J Reprod Immunol. 2010;63(6):566–75.
3. Hickey DK, Patel MV, Fahey JV, Wira CR. Innate and adaptive immunity at
mucosal surfaces of the female reproductive tract: stratification and
integration of immune protection against the transmission of sexually
transmitted infections. J Reprod Immunol. 2011;88(2):185–94.
4. Horbul JE, Schmechel SC, Miller BR, Rice SA, Southern PJ. Herpes simplex
virus-induced epithelial damage and susceptibility to human
immunodeficiency virus type 1 infection in human cervical organ culture.
PLoS One. 2011;6(7), e22638.
5. Reis Machado J, da Silva MV, Cavellani CL, dos Reis MA, Monteiro ML,
Teixeira Vde P, Miranda Corrêa RR. Mucosal Immunity in the Female Genital
Tract, HIV/AIDS. BioMed Research International. 2014, 2014:20. doi:10.1155/
2014/350195.
6. White RG. Curable sexually transmitted infection treatment interventions to
prevent HIV transmission in sub-Saharan Africa. Open Infct Dis J. 2009;3:
148–55.
7. Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted
co-infections in people living with HIV/AIDS: systematic review with
implications for using HIV treatments for prevention. Sex Transm Infect.
2011;87(3):183–90.
8. Reddy B, Rastogi S, Das B, Salhan S, Verma S, Mittal A. Cytokine expression
pattern in the genital tract of chlamydia trachomatis positive infertile
women—implication for T‐cell responses. Clin Exp Immunol. 2004;137(3):
552–8.
9. Sperling R, Kraus TA, Ding J, Veretennikova A, Lorde-Rollins E, Singh T, et al.
Differential profiles of immune mediators and in vitro HIV infectivity
between endocervical and vaginal secretions from women with chlamydia
trachomatis infection: a pilot study. J Reprod Immunol. 2013;99(1–2):80–7.
10. Mlisana K, Naicker N, Werner L, Roberts L, van Loggerenberg F, Baxter C, et
al. Symptomatic vaginal discharge is a poor predictor of sexually
transmitted infections and genital tract inflammation in high-risk women in
South Africa. J Infect Dis. 2012;206(1):6–14.
11. Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV
incidence. Aids. 2009;23(12):1595–8.
12. Weiss H, Buve A, Robinson N, Van Dyck E, Kahindo M, Anagonou S, et al.
The epidemiology of HSV-2 infection and its association with HIV infection
in four urban African populations. Aids. 2001;15:S97–S108.
13. Abbai NS, Wand H, Ramjee G. Socio-demographic and behavioural
characteristics associated with HSV-2 sero-prevalence in high risk women in
KwaZulu-Natal. BMC Research Notes. 2015;8(1):185.
14. Burgener A, McGowan I, Klatt NR. HIV and mucosal barrier interactions:
consequences for transmission and pathogenesis. Curr Opin Immunol. 2015;
36:22–30.
15. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K,
et al. Diaphragm and lubricant gel for prevention of HIV acquisition in
southern African women: a randomised controlled trial. Lancet. 2007;
370(9583):251–61.
16. Moench TR, Chipato T, Padian NS. Preventing disease by protecting the
cervix: the unexplored promise of internal vaginal barrier devices. Aids.
2001;15(13):1595–602.
17. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, et
al. Disruption of tight junctions by cellulose sulfate facilitates HIV infection:
model of microbicide safety. J Infect Dis. 2009;200(4):599–608.
18. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV
transmission. Nat Rev Microbiol. 2004;2(1):33–42.
19. Morse SA, Trees DL, Htun Y, Radebe F, Orle KA, Dangor Y, et al. Comparison
of clinical diagnosis and standard laboratory and molecular methods for the
diagnosis of genital ulcer disease in Lesotho: association with human
immunodeficiency virus infection. J Infect Dis. 1997;175(3):583–9.
20. Hayes R, Watson-Jones D, Celum C, van de Wijgert J, Wasserheit J.
Treatment of sexually transmitted infections for HIV prevention: end of the
road or new beginning? London, England: AIDS; 2010, 24(0 4). doi:10.1097/
01.aids.0000390704.35642.47.
21. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis
and HIV acquisition: a meta-analysis of published studies. AIDS (London,
England). 2008;22(12):1493.
22. Greenblatt RM, Bacchetti P, Barkan S, Augenbraun M, Silver S, Delapenha R,
et al. Lower genital tract infections among HIV‐infected and high‐risk
uninfected women: findings of the Women's interagency HIV study (WIHS).
Sex Transm Dis. 1999;26(3):143–51.
23. Dickerson MC, Johnston J, Delea TE, White A, Andrews E. The causal role for
genital ulcer disease as a risk factor for transmission of human
immunodeficiency virus: an application of the Bradford hill criteria. Sex
Transm Dis. 1996;23(5):429–40.
24. Røttingen J-A, Cameron DW, Garnett GP. A systematic review of the
epidemiologic interactions between classic sexually transmitted diseases
and HIV: how much really is known? Sex Transm Dis. 2001;28(10):579–97.
25. Yeaman GR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, et al.
Chemokine receptor expression in the human ectocervix: implications for
infection by the human immunodeficiency virus‐type I. Immunology. 2004;
113(4):524–33.
26. Howell AL, Asin SN, Yeaman GR, Wira CR. HIV-1 infection of the female
reproductive tract. Curr HIV/AIDS Rep. 2005;2(1):35–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Abbai et al. BMC Women's Health  (2016) 16:19 Page 7 of 7
